Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
Abstract Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based chemotherapy. We wished to determine if...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
BMC
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/935991f59d184ddaad6383fdb13febcd |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|